Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS
Phase of Trial: Phase III
Latest Information Update: 25 Apr 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LONESTAR
- 11 Apr 2019 Planned End Date changed from 1 Dec 2022 to 31 Dec 2022.
- 11 Apr 2019 Planned primary completion date changed from 1 Dec 2022 to 31 Dec 2022.
- 02 Nov 2018 Planned End Date changed from 1 Dec 2023 to 1 Dec 2022.